3 results
A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes
The primary objective is to confirm that treatment with oral semaglutide does not result in an unacceptable increase in cardiovascular risk compared to placebo (rule out 80% excess risk) in subjects with T2D at high risk of cardiovascular events.The…
Approved WMOCompleted
The aim of this study is to investigate the possible consequences of generic-generic substitution of gabapentin, a frequently used anti-epileptic drug.
Approved WMOCompleted
Study IM011-077 is a Phase 2 randomized, open-label, multicenter clinical study designed to assess the safety and tolerability, efficacy and biomarker response of deucravacitinib 6 mg BID (twice daily) in subjects with moderate to severe Ulcerative…